View in EDS PDF Full Text

Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer.

Saved in:
Bibliographic Details
Title: Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer.
Authors: Zeller T; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany., Münnich IA; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany., Windisch R; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany., Hilger P; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany., Schewe DM; Medical Faculty, Otto-von-Guericke University Magdeburg, Magdeburg, Germany., Humpe A; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany., Kellner C; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany.
Source: Frontiers in immunology [Front Immunol] 2023 Sep 13; Vol. 14, pp. 1240275. Date of Electronic Publication: 2023 Sep 13 (Print Publication: 2023).
Publication Type: Journal Article; Review; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37781391
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Zeller+T%22">Zeller T</searchLink>; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Münnich+IA%22">Münnich IA</searchLink>; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Windisch+R%22">Windisch R</searchLink>; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Hilger+P%22">Hilger P</searchLink>; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Schewe+DM%22">Schewe DM</searchLink>; Medical Faculty, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.<br /><searchLink fieldCode="AU" term="%22Humpe+A%22">Humpe A</searchLink>; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Kellner+C%22">Kellner C</searchLink>; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2023 Sep 13; Vol. 14, pp. 1240275. <i>Date of Electronic Publication: </i>2023 Sep 13 (<i>Print Publication: </i>2023).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37781391
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fimmu.2023.1240275
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1240275
    Titles:
      – TitleFull: Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Zeller T
      – PersonEntity:
          Name:
            NameFull: Münnich IA
      – PersonEntity:
          Name:
            NameFull: Windisch R
      – PersonEntity:
          Name:
            NameFull: Hilger P
      – PersonEntity:
          Name:
            NameFull: Schewe DM
      – PersonEntity:
          Name:
            NameFull: Humpe A
      – PersonEntity:
          Name:
            NameFull: Kellner C
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 13
              M: 09
              Text: 2023 Sep 13
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1664-3224
          Numbering:
            – Type: volume
              Value: 14
          Titles:
            – TitleFull: Frontiers in immunology
              Type: main
ResultId 1